Abstract

Small drug molecules usually bind to multiple protein targets or even unintended off-targets. Such drug promiscuity has often led to unwanted or unexplained drug reactions, resulting in side effects or drug repositioning opportunities. So it is always an important issue in pharmacology to identify potential drug-target interactions (DTI). However, DTI discovery by experiment remains a challenging task, due to high expense of time and resources. Many computational methods are therefore developed to predict DTI with high throughput biological and clinical data. Here, we initiatively demonstrate that the on-target and off-target effects could be characterized by drug-induced in vitro genomic expression changes, e.g. the data in Connectivity Map (CMap). Thus, unknown ligands of a certain target can be found from the compounds showing high gene-expression similarity to the known ligands. Then to clarify the detailed practice of CMap based DTI prediction, we objectively evaluate how well each target is characterized by CMap. The results suggest that (1) some targets are better characterized than others, so the prediction models specific to these well characterized targets would be more accurate and reliable; (2) in some cases, a family of ligands for the same target tend to interact with common off-targets, which may help increase the efficiency of DTI discovery and explain the mechanisms of complicated drug actions. In the present study, CMap expression similarity is proposed as a novel indicator of drug-target interactions. The detailed strategies of improving data quality by decreasing the batch effect and building prediction models are also effectively established. We believe the success in CMap can be further translated into other public and commercial data of genomic expression, thus increasing research productivity towards valid drug repositioning and minimal side effects.

Highlights

  • Drug promiscuity refers to the phenomenon that small molecule drug binds to multiple protein targets

  • There are researches addressing drug-induced target expression [18], it has been rarely studied that drug-induced downstream gene-expression changes may directly indicate target promiscuity, missing a possible technique of drug-target interactions (DTI) discovery

  • We initiatively demonstrated that target binding is directly correlated with drug induced genomic expression profiles in Connectivity Map (CMap)

Read more

Summary

Introduction

Drug promiscuity refers to the phenomenon that small molecule drug binds to multiple protein targets. It is observed that the BAES significantly outperforms the unadjusted expression similarity [26], in terms of scoring compound pairs that share at least one target in DrugBank (Figure 3) This test corroborates that after batch effect adjustment, CMap expression profiles would better characterize the genomic reactions of ligand binding. The well characterized targets with robust ROC curve (i.e. the lower bound of AUC confidence interval is over 0.50) and significant benchmark enrichment (i.e. the p-value is less than 0.05) are more likely to be found among neurotransmitter receptors, ion channels, nuclear receptors and cyclooxygenases Such distinction of performance indicates that the ligands binding of some targets, but not others, can result in extensive and intensive changes at mRNA level, which is exactly detectable in CMap. So instead of building a universal model to predict interactions across all drugs and targets, we suggest that specified models should be established for individual targets (especially the targets well characterized by CMap), in order to increase the chance of detecting true DTI. By activating CMap and other transcriptomic data sources, gene-expression information would be readily integrated into DTI discovery pipelines in subsequent studies

Normalization of batch variation in CMap expression profiles
Naıve model measuring the likelihood of potential drugtarget interactions
PN BAESi
Author Contributions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call